Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats

被引:47
作者
Rogoz, Zofia [1 ]
Skuza, Grazyna [1 ]
机构
[1] Polish Acad Sci, Inst Pharmacol, Dept Pharmacol, PL-31343 Krakow, Poland
关键词
olanzapine; risperidone; fluoxetine; elevated plus-maze test; rats; POSTTRAUMATIC-STRESS-DISORDER; OBSESSIVE-COMPULSIVE DISORDER; FORCED SWIMMING TEST; ATYPICAL ANTIPSYCHOTICS; AUGMENTATION; DEPRESSION; THERAPY; MICE;
D O I
10.1016/S1734-1140(11)70719-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study was examined the effect of treatment with olanzapine or risperidone, given separately or in combination with fluoxetine, in the elevated plus-maze test (an animal model of anxiety) in male Wistar rats. The obtained results showed that treatment with olanzapine (1 mg/kg), risperidone (0.1 and 0.3 mg/kg) or fluoxetine (5 and 10 mg/kg) induced an anxiolytic-like effect in the elevated plus-maze test. Olanzapine, risperidone and fluoxetine, tested in doses effective in the model of anxiolytic-like actions, did not affect motor coordination, while olanzapine (3 mg/kg) and risperidone (0.3 mg/kg) produced a significant reduction of exploratory activity in the open field test. In a combination study, the anxiolytic-like effect of olanzapine or risperidone was significantly antagonized by co-treatment with fluoxetine. Additionally, co-treatment with olanzapine or risperidone and fluoxetine disturbed the motor coordination of rats in a rota-rod test. These findings indicate that olanzapine, risperidone and fluoxetine per se may be clinically effective in treating anxiety disorders, but their effects may be attenuated when they are used in combination with other medications.
引用
收藏
页码:1547 / 1552
页数:6
相关论文
共 25 条
[1]  
Bobo WV, 2009, NEUROPSYCH DIS TREAT, V5, P369
[2]   Atypical uses of atypical antipsychotics [J].
Brooke, NS ;
Wiersgalla, M ;
Salzman, C .
HARVARD REVIEW OF PSYCHIATRY, 2005, 13 (06) :317-339
[3]   Olanzapine in the treatment of post-traumatic stress disorder: a pilot study [J].
Butterfield, MI ;
Becker, ME ;
Connor, KM ;
Sutherland, S ;
Churchill, LE ;
Davidson, JRT .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (04) :197-203
[4]  
Carson William H, 2004, Psychopharmacol Bull, V38, P38
[5]   Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors [J].
Dhir, Ashish ;
Kulkarni, S. K. .
NEUROSCIENCE LETTERS, 2008, 445 (01) :83-88
[6]   Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms [J].
Hammer, MB ;
Faldowski, RA ;
Ulmer, HG ;
Frueh, BC ;
Huber, MG ;
Arana, GW .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (01) :1-8
[7]  
Hamner MB, 1996, AM J PSYCHIAT, V153, P841
[8]   Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study [J].
Hollander, E ;
Rossi, NB ;
Sood, E ;
Pallanti, S .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (04) :397-401
[9]   Behavioural effects of chronic haloperidol and risperidone treatment in rats [J].
Karl, Tim ;
Duffy, Liesl ;
O'Brien, Elizabeth ;
Matsumoto, Izuru ;
Dedova, Irina .
BEHAVIOURAL BRAIN RESEARCH, 2006, 171 (02) :286-294
[10]   A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression [J].
Keitner, Gabor I. ;
Garlow, Steven J. ;
Ryan, Christine E. ;
Ninan, Philip T. ;
Solomon, David A. ;
Nemeroff, Charles B. ;
Keller, Martin B. .
JOURNAL OF PSYCHIATRIC RESEARCH, 2008, 43 (03) :205-214